Home/ Supplements/ Vitamin K/ Ultra Preventive IX With Vitamin K

Ultra Preventive IX With Vitamin K

product on market Tablet or Pill Douglas Laboratories Safety: 98/100
98/100

This product looks safe

  • Niacin/Niacinamide: 190mg is 5.4× the Tolerable Upper Intake Level (35mg)
  • Magnesium Complex: 500mg is 1.4× the Tolerable Upper Intake Level (350mg)
  • Manganese: 20mg is 1.8× the Tolerable Upper Intake Level (11mg)
  • 50% of ingredients have research evidence
F Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

This formula contains a blend of fat-soluble and antioxidant vitamins that support immune function and bone health. There is strong clinical evidence supporting the roles of vitamins A, C, D, and K in maintaining systemic wellness. However, the overall evidence coverage for this specific combination is limited.

AI-generated summary based on research evidence. Not medical advice.

Alerts

Safety Alerts

Niacin/Niacinamide: 190mg is 5.4× the Tolerable Upper Intake Level (35mg)

Magnesium Complex: 500mg is 1.4× the Tolerable Upper Intake Level (350mg)

Manganese: 20mg is 1.8× the Tolerable Upper Intake Level (11mg)

Label

Product Label

Label for Ultra Preventive IX With Vitamin K
Open Full PDF View on NIH DSLD →
Details

Label Data

7 Tablet(s)
Serving Size
14
Servings
Other Combinations
Product Type
50%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Vitamin A
25000 IU (500% DV)
Vitamin C
1200 mg (2000% DV)
400 IU (100% DV)
Within RDA (0.7× RDA) 608 studies (A:16, B:251)
400 IU (1333% DV)
17.9× RDA — above typical dose (UL: 1000 mg) 179 studies (A:3, B:90)
70 mcg (88% DV)
Within RDA (0.6× RDA) 275 studies (A:9, B:175)
100 mg (6667% DV)
83.3× RDA — above typical dose 76 studies (A:0, B:33)
50 mg (2941% DV)
38.5× RDA — above typical dose 13 studies (A:0, B:1)
190 mg (950% DV)
Exceeds UL by 5.4× (UL: 35 mg) 196 studies (A:5, B:63)
Vitamin B-6 Complex
100 mg (5000% DV)
800 mcg (200% DV)
2.0× RDA — within safe limits 226 studies (A:10, B:105)
100 mcg (1667% DV)
41.7× RDA — above typical dose 139 studies (A:1, B:44)
300 mcg (100% DV)
10.0× RDA — above typical dose 27 studies (A:0, B:11)
500 mg (5000% DV)
100.0× RDA — above typical dose 2 studies — no high-quality reviews
Calcium
500 mg (50% DV)
200 mcg (133% DV)
1.3× RDA — within safe limits 245 studies (A:4, B:133)
500 mg (125% DV)
Exceeds UL by 1.4× (UL: 350 mg) 316 studies (A:8, B:159)
25 mg (167% DV)
2.3× RDA — within safe limits 263 studies (A:6, B:134)
200 mcg (286% DV)
3.6× RDA — above typical dose (UL: 0.4 mg) 173 studies (A:0, B:67)
2 mg (100% DV)
2.2× RDA — within safe limits 37 studies (A:0, B:11)
20 mg (1000% DV)
Exceeds UL by 1.8× (UL: 11 mg) 9 studies — no high-quality reviews
200 mcg (167% DV)
5.7× RDA — above typical dose 199 studies (A:1, B:55)
100 mcg (133% DV)
2.2× RDA — within safe limits 3 studies — no high-quality reviews
Potassium
99 mg (3% DV)
60 mg
Within RDA (0.1× RDA) 38 studies (A:1, B:7)
100 mg
Market median: 550.0mg (217 products) 29 studies (A:0, B:5)
Market median: 500.0mg (283 products) 174 studies (A:0, B:62)
50 mg
Market median: 500.0mg (9 products) 7 studies — no high-quality reviews
50 mcg
Market median: 0.5mg (6 products) 1 studies (A:0, B:1)
1.5 mg
Market median: 3.0mg (58 products) 3 studies — no high-quality reviews
Trace Elements
100 mcg
L-Cysteine/N-Acetyl-L-Cysteine
200 mg
12.5 mg
Market median: 500.0mg (193 products) 7 studies — no high-quality reviews
Glutamic Acid
20 mg
114 mg
Market median: 496.0mg (192 products) 20 studies — no high-quality reviews
Pycnogenol(R)
25 mg
Market median: 100.0mg (284 products) 10 studies (A:0, B:4)
Market median: 120.0mg (440 products) 191 studies (A:1, B:71)
Eleutherococcus Senticosus
25 mg
Market median: 400.0mg (380 products) 36 studies (A:1, B:10)
Market median: 400.0mg (380 products) 36 studies (A:1, B:10)
100 mg
Market median: 500.0mg (497 products) 135 studies (A:0, B:40)
Green Papaya Extract
100 mg
Beet Extract
50 mg
Apple Pectin
50 mg
50 mg
Market median: 200.0mg (136 products) 3 studies — no high-quality reviews
Rose Hips
100 mg
Market median: 500.0mg (283 products) 174 studies (A:0, B:62)
Market median: 500.0mg (19 products)
2.4 mg
Market median: 108.0mg (8 products) 9 studies (A:0, B:4)
Hesperidin Complex
10 mg
Special Ultra Preventive(R) Green Base Proprietary Blend
550 mg
Ultra Preventive(R) Green Base

Other Ingredients

Cellulose Vegetable Stearate
Claims

Label Claims — Verification

Unverified Nutrient
Unverified All Other
Info

Product Information

Directions for Use

Suggested Usage: As a dietary supplement, adults take 7 tablets daily or as directed by your healthcare professional. This product is best taken with meals.

Warnings & Precautions

KEEP OUT OF REACH OF CHILDREN.

Tamper resistant package, do not use if outer seal is missing.

WARNING: This product contains Vitamin K, which interferes with the prescription drugs COumadin(R) and Warfarin. No not take this if taking either of these drugs.

Formulation Notes

This product contains NO yeast, soy protein, milk/dairy, corn, sodium, sugar, starch, artificial coloring, preservatives or flavoring.

Ultra Preventive IX With Vitamin K

Additional Information

For optimal storage conditions, store in a cool, dry place. (59(0)-77(0)F/15(0)-25(0)C) (35-65% relative humidity)

Pycnogenol(R) - French maritime bark extract-(TM)

Formula #84551

Metadata

Product Details

UPC / SKU3 10539 01931 3
DSLD Entry Date2012-06-25
Product TypeOther Combinations
FormTablet or Pill
DSLD ID10259
Data Updated2026-04-11
Research

Research Evidence

332
Research Sources
59
Avg Quality
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022 PubMed DOI
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013 PubMed DOI
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
View all evidence for Vitamin K →
Compare

Similar Products

View all Vitamin K products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.